Cozad Asset Management Inc. Trims Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Cozad Asset Management Inc. lowered its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 90.2% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 320 shares of the biopharmaceutical company's stock after selling 2,953 shares during the period. Cozad Asset Management Inc.'s holdings in Regeneron Pharmaceuticals were worth $203,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of the business. Marietta Wealth Management LLC raised its holdings in shares of Regeneron Pharmaceuticals by 30.2% during the first quarter. Marietta Wealth Management LLC now owns 10,778 shares of the biopharmaceutical company's stock valued at $6,836,000 after purchasing an additional 2,501 shares during the last quarter. Pamalican Asset Management Ltd purchased a new stake in Regeneron Pharmaceuticals during the fourth quarter valued at approximately $4,915,000. Rhenman & Partners Asset Management AB raised its position in Regeneron Pharmaceuticals by 11.4% in the fourth quarter. Rhenman & Partners Asset Management AB now owns 43,457 shares of the biopharmaceutical company's stock worth $30,956,000 after acquiring an additional 4,457 shares during the period. GAMMA Investing LLC boosted its stake in shares of Regeneron Pharmaceuticals by 89,825.0% during the 1st quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company's stock worth $517,291,000 after acquiring an additional 814,713 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its position in shares of Regeneron Pharmaceuticals by 3.9% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 25,629 shares of the biopharmaceutical company's stock valued at $16,255,000 after acquiring an additional 955 shares during the period. Institutional investors own 83.31% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have recently commented on REGN. Royal Bank Of Canada lowered Regeneron Pharmaceuticals from a "moderate buy" rating to a "hold" rating and set a $662.00 price objective for the company. in a research note on Friday, May 30th. Wall Street Zen lowered Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Thursday, May 1st. Canaccord Genuity Group restated a "buy" rating and issued a $850.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Wednesday, July 23rd. UBS Group restated a "neutral" rating on shares of Regeneron Pharmaceuticals in a research note on Friday. Finally, The Goldman Sachs Group reduced their price objective on Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating for the company in a research note on Wednesday, April 30th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, sixteen have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $837.61.

Regeneron Pharmaceuticals Stock Up 2.5%

REGN stock traded up $13.41 during midday trading on Friday, reaching $558.87. 1,656,418 shares of the company were exchanged, compared to its average volume of 858,977. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.03 and a current ratio of 4.93. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $1,211.20. The stock's 50-day simple moving average is $538.05 and its 200 day simple moving average is $604.08. The company has a market cap of $60.34 billion, a price-to-earnings ratio of 14.23, a price-to-earnings-growth ratio of 2.05 and a beta of 0.33.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). The business had revenue of $3.03 billion during the quarter, compared to analyst estimates of $3.40 billion. Regeneron Pharmaceuticals had a net margin of 31.94% and a return on equity of 15.27%. The business's revenue was down 3.7% compared to the same quarter last year. During the same period in the previous year, the firm earned $9.55 earnings per share. On average, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th were paid a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend was Tuesday, May 20th. Regeneron Pharmaceuticals's payout ratio is currently 8.96%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.